10,688 Shares in ANI Pharmaceuticals, Inc. $ANIP Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company bought a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the second quarter, Holdings Channel reports. The fund bought 10,688 shares of the specialty pharmaceutical company’s stock, valued at approximately $885,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals during the 1st quarter valued at approximately $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of ANI Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after acquiring an additional 470 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of ANI Pharmaceuticals by 0.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after acquiring an additional 423 shares during the last quarter. Jane Street Group LLC bought a new position in shares of ANI Pharmaceuticals during the first quarter valued at $2,706,000. Finally, Norges Bank purchased a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth about $625,000. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP opened at $71.23 on Friday. ANI Pharmaceuticals, Inc. has a one year low of $70.15 and a one year high of $99.50. The stock has a 50-day moving average of $78.62 and a 200 day moving average of $78.44. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of 15.35 and a beta of 0.45.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.04 by $0.17. The business had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Insider Activity

In related news, CFO Stephen Carey sold 3,313 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total transaction of $284,918.00. Following the transaction, the chief financial officer owned 177,543 shares in the company, valued at $15,268,698. This represents a 1.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $77.00, for a total transaction of $243,474.00. Following the completion of the sale, the senior vice president owned 75,534 shares in the company, valued at $5,816,118. This represents a 4.02% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 23,925 shares of company stock valued at $1,890,145 over the last three months. Corporate insiders own 8.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ANIP. Guggenheim cut their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Finally, Canaccord Genuity Group lowered their price objective on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $105.83.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.